Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.42 |
| ▸ | BID | P55957 | 2/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17678365 | 0.98 | GPR84 (0.53) | GPR84PTGS2HAO1CYP3A4KAT8 | |
| SCHEMBL17678362 | 0.91 | GPR84 (0.50) | GPR84PTGS2HAO1KAT8PPARA | |
| SCHEMBL17678367 | 0.89 | GPR84 (0.51) | GPR84PTGS2HAO1CYP3A4KAT8 | |
| SCHEMBL16050765 | 0.88 | ALDH1A1 (0.54) | GPR84PTGS2CYP3A4KAT8PPARA | |
| SCHEMBL28547589 | 0.87 | ALDH1A1 (0.53) | GPR84PTGS2CYP3A4KAT8PPARA | |
| SCHEMBL29555599 | 0.86 | ALDH1A1 (0.56) | GPR84PTGS2CYP3A4KAT8PPARA | |
| SCHEMBL16050413 | 0.86 | ALDH1A1 (0.56) | GPR84PTGS2CYP3A4KAT8PPARA | |
| SCHEMBL19166230 | 0.85 | PTGS2 (0.50) | GPR84PTGS2CYP3A4KAT8PPARA | |
| SCHEMBL28161013 | 0.85 | ALDH1A1 (0.54) | GPR84PTGS2CYP3A4KAT8PPARA | |
| SCHEMBL10885674 | 0.84 | PTGS2 (0.64) | PTGS2CYP3A4ALDH1A1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209399-A1 | Substituted Aromatic Compounds and Pharmaceutical Compositions For The Prevention And Treatment Of Diabetes | PROMETIC PHARMA SMT LIMITED (GB) | 2017-07-27 | — | — | US | disclosed |
| WO-2016054726-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DIABETES | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016054728-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209399-A1 | Substituted Aromatic Compounds and Pharmaceutical Compositions For The Prevention And Treatment Of Diabetes | GPR119, LIPC, INSR | GPR84 1382/4885PTGS2 2425/4885HAO1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.